Bezafibrate is a well established pan-PPAR activator. This fibrate drug has over 25 years of therapeutic use with a good safety profile. The fibrate class of drugs are generally known as PPARα agonists, but bezafibrate appears to activate PPAR.delta. and PPARγ as well. Bezafibrate activates human PPARα, PPAR.delta., and PPARγ with EC50 values of 50, 20, and 60 μM, respectively, in a cell-based transcription assay.{10670} Bezafibrate is used to treat hyperlipidemia. It helps lower LDL cholesterol and triglycerides while raising HDL cholesterol levels. It also improves insulin sensitivity and reduces blood glucose levels, which in combination with the cholesterol effects significantly lowers the incidence of cardiovascular events and development of diabetes in patients with features of metabolic syndrome.{14916}